Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Marco Gerlinger

Back to Search
Savy T, Flanders L, Karpanasamy T, Sun M, Gerlinger M ( 2025 ) . Cancer evolution: from Darwin to the Extended Evolutionary Synthesis . Trends in Cancer vol. 11 , ( 3 ) 204 - 215 .
Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, Yousefi R, May A et al. ( 2024 ) . Resistance Management for Cancer: Lessons from Farmers . Cancer Research vol. 84 , ( 22 ) 3715 - 3727 .
Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, Wang Z, Wang G et al. ( 2024 ) . STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer . Future Oncology vol. 20 , ( 24 ) 1733 - 1743 .
Challoner BR, Slater SC, Sansano HB, Aresu M, Bryant A, Chen H-C, Begum R, Rana T et al. ( 2024 ) . 30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC) . Annals of Oncology vol. 35 ,
Buzzetti M, Gerlinger M ( 2023 ) . Assessing the toxicity of bispecific antibodies . Nature Biomedical Engineering vol. 8 , ( 4 ) 339 - 340 .
Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M ( 2023 ) . Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ . Cancer Research Communications vol. 3 , ( 11 ) 2345 - 2357 .
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. ( 2023 ) . Genetic and immune landscape evolution in MMR‐deficient colorectal cancer . The Journal of Pathology vol. 262 , ( 2 ) 226 - 239 .
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G et al. ( 2022 ) . Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors . JCO Precision Oncology vol. 6 , ( 6 )
Back to Search